Christopherson W M
Clin Obstet Gynaecol. 1986 Dec;13(4):673-93.
Endometrial carcinoma includes several specific subtypes which have differing prognostic implications. The two most common subtypes are adenocarcinoma, not otherwise specified (NOS), and adenoacanthoma. Also included in the adenocarcinoma NOS are secretory carcinoma and mucinous carcinoma which have the same natural history as do adenocarcinomas without these features. Fortunately, the above types have the best prognosis and constitute approximately 80% of all endometrial carcinomas. They also present the major diagnostic problem for the pathologist in distinguishing atypical hyperplasia and some of the metaplasias from well-differentiated carcinoma. The tendency would appear to be the over-interpretation of these hyperplastic lesions. Other subtypes have a much less favorable outlook. They include papillary carcinoma, adenosquamous carcinoma, glassy cell carcinoma and clear cell carcinoma. There are two distinct types of papillary carcinoma, the papillary clear cell and the papillary nonclear cell carcinoma. These can readily be separated, and should be, on the basis of prognostic implications. Other pathologic parameters play a significant role in patient management and in the estimation of prognosis. These include postsurgical pathological staging, measurement of depth of myometrial invasion, lymphatic and blood-vascular invasion, serosal involvement, local spread and, perhaps most importantly, tumor grade. Nuclear grading proved to be a better predictor of treatment outcome than did either the FIGO or WHO grading systems. This was especially true in adenocarcinoma NOS, adenoacanthoma and papillary carcinoma.
子宫内膜癌包括几种具有不同预后意义的特定亚型。两种最常见的亚型是未另行特指的腺癌(NOS)和腺棘皮癌。NOS腺癌还包括分泌性癌和黏液癌,它们与无这些特征的腺癌具有相同的自然病程。幸运的是,上述类型预后最佳,约占所有子宫内膜癌的80%。它们也给病理学家带来了主要的诊断难题,即在区分非典型增生和某些化生与高分化癌方面。趋势似乎是对这些增生性病变过度解读。其他亚型的预后则要差得多。它们包括乳头状癌、腺鳞癌、玻璃样细胞癌和透明细胞癌。乳头状癌有两种不同类型,即乳头状透明细胞癌和乳头状非透明细胞癌。基于预后意义,它们很容易区分,也应该区分。其他病理参数在患者管理和预后评估中起着重要作用。这些包括术后病理分期、肌层浸润深度测量、淋巴和血管浸润、浆膜受累、局部扩散,也许最重要的是肿瘤分级。核分级被证明比国际妇产科联合会(FIGO)或世界卫生组织(WHO)分级系统更能预测治疗结果。在NOS腺癌、腺棘皮癌和乳头状癌中尤其如此。